| 1. |
- Abdullah, Laila, et al.
(författare)
-
The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial.
- 2020
-
Ingår i: Frontiers in neurology. - : Frontiers Media SA. - 1664-2295. ; 11
-
Tidskriftsartikel (refereegranskat)abstract
- We examined the effects of a dihydropyridine calcium channel blocker nilvadipine with anti-inflammatory properties on cognition and cerebrospinal fluid (CSF) biomarkers by baseline Alzheimer's disease (AD) severity. Exploratory analyses were performed on the dataset (n = 497) of a phase III randomized placebo-controlled trial to examine the response to nilvadipine in AD subjects stratified by baseline AD severity into very mild (MMSE ≥ 25), mild (MMSE 20-24) and moderate AD (MMSE < 20). The outcome measures included total and subscale scores of the Alzheimer's Disease Assessment Scale Cognitive 12 (ADAS-Cog 12), the Clinical Dementia Rating Scale sum of boxes (CDR-sb) and the AD composite score (ADCOMS). Cerebrospinal fluid biomarkers Aβ38, Aβ40, Aβ42, neurofilament light chain (NFL), neurogranin, YKL-40, total tau and P181 tau (ptau) were measured in a subset of samples (n = 55). Regression analyses were adjusted for confounders to specifically examine the influence of nilvadipine and baseline AD severity on cognitive outcomes over 78-weeks. Compared to their respective placebo-controls, nilvadipine-treated, very mild AD subjects showed less decline, whereas moderate AD subjects showed a greater cognitive decline on the ADAS-Cog 12 test and the ADCOMS. A lower decline was observed after nilvadipine treatment for a composite memory trait in very mild AD subjects and a composite language trait in mild AD subjects. Cerebrospinal fluid Aβ42/Aβ40 ratios were increased in mild AD and decreased in moderate AD patients treated with nilvadipine, compared to their respective controls. Among moderate AD subjects, levels of ptau, total tau, neurogranin and YKL-40 increased in subjects treated with nilvadipine compared to placebo. These studies suggest that baseline AD severity influenced the treatment outcome in the NILVAD trial and that future clinical trials of nilvadipine should be restricted to mild and very mild AD patients. Trial Registration: NCT02017340 Registered 20 December 2013, https://clinicaltrials.gov/ct2/show/NCT02017340 EUDRACT Reference Number 2012-002764-27 Registered 04 February 2013, https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002764-27.
|
|
| 2. |
- Bastian, Anne, et al.
(författare)
-
Explaining “peak car” with economic variables
- 2016
-
Ingår i: Transportation Research Part A. - : Elsevier. - 0965-8564 .- 1879-2375. ; 2016:88, s. 236-250
-
Tidskriftsartikel (refereegranskat)abstract
- Many western countries have seen a plateau and subsequent decrease of car travel during the 21st century. What has generated particular interest and debate is the statement that the development cannot be explained by changes in traditional explanatory factors such as GDP and fuel prices. Instead, it has been argued, the observed trends are indications of substantial changes in lifestyles, preferences and attitudes to car travel; what we are experiencing is not just a temporary plateau, but a true “peak car”. However, this study shows that the traditional variables GDP and fuel price are in fact sufficient to explain the observed trends in car traffic in all the countries included in our study: the United States, France, the United Kingdom, Sweden and (to a large extent) Australia and Germany. We argue that the importance of the fuel price increases in the early 2000s has been underappreciated in the studies that shaped the later debate. Results also indicate that GDP elasticities tend to decrease with rising GDP, and that fuel price elasticities tend to increase at high price levels and during periods of rapid price increases.
|
|
| 3. |
- Bastian, Anne
(författare)
-
Explaining Trends in Car Use
- 2017
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- Many western countries have seen a plateau and subsequent decline in car travel during the early 21st century. What has generated particular interest and debate is the claim that the development cannot only be explained by changes in traditional explanatory factors such as GDP, fuel prices and land-use. Instead, it has been argued, the observed trends are indications of substantial changes in lifestyles, preferences and attitudes to car travel and thus, not just a temporary plateau but a true peak in car use.This thesis is a compilation of five papers, studying the issue on a national, international, regional and city scale through quantitative analysis of aggregate administrative data and individual travel survey data. It concludes that the aggregate development of car travel per capita can be explained fairly well with the traditional model variables GDP and fuel price. Furthermore, this thesis shows that spatial context and policy become increasingly important in car use trends: car use diverges over time between city, suburban and rural residents of Sweden and other European countries, while gender and to some extent income become less differentiating for car use.
|
|
| 4. |
- Bastian, Anne, et al.
(författare)
-
Peak car? : Drivers of the recent decline in Swedish car use
- 2015
-
Ingår i: Transport Policy. - : Elsevier BV. - 0967-070X .- 1879-310X. ; 42, s. 94-102
-
Tidskriftsartikel (refereegranskat)abstract
- It has long been well-known that economic variables such as GDP and fuel price as well as socio-demographic characteristics and spatial distribution are key factors explaining car use trends. However, due. to the recently observed plateau of total car travel in many high income countries, it has been argued that other factors, such as changes in preferences, attitudes and life-styles, have become more important drivers of car use. This paper shows that the two variables, GDP per capita and fuel price, explain most of the aggregate trends in car distances driven per adult in Sweden: as much as 80% over the years 2002 to 2012. The estimated elasticities are well in line with previous literature and can reasonably well reproduce the trend in car distances driven per adult back to 1980. We find, however, a substantial variation in elasticities between municipalities depending on public transport supply, population density, share of foreign-born inhabitants and the average income level.
|
|
| 5. |
- Bastian, Anne, et al.
(författare)
-
Peak Car? : Drivers of the recent decline in Swedish car use
- 2014
-
Konferensbidrag (refereegranskat)abstract
- It has long been well-known that economic variables such as GDP and fuel price as well as socio-demographic characteristics and spatial distribution are key factors explaining car use trends. However, due to the recently observed plateau of total car travel in many high income countries, it has been argued that other factors, such as changes in preferences, attitudes and life-styles, have become more important drivers of car use. This paper shows that the two variables GDP per capita and fuel price explain most of the aggregate trends in car distances driven per adult in Sweden: as much as 80% over the years 2002 to 2012. The estimated elasticities are well in line with previous literature and can reasonably well reproduce the trend in car distances driven per adult back to 1980. We find, however, a substantial variation in elasticities between municipalities depending on public transport supply, population density, share of foreign-born inhabitants and the average income level.
|
|
| 6. |
- Bastian, Anne, et al.
(författare)
-
Peak Car for urban Swedish men?
- 2014
-
Ingår i: Proceedings of Symposium of the European Association for Research in Transportation (hEART),September 10, 2014 – September 12, 2014, Leeds, UK.
-
Konferensbidrag (refereegranskat)abstract
- We study long-term trends in regional car travel demand within and across socio-demographic groups in Sweden, using cross-sectional data from National Travel Surveys, spanning the period from 1978 to 2011. We find that the reduction in per-adult driving in Sweden mainly occurs among urban men. Urban men of all income groups reduced their driving for both commuting and non-commuting trips in conjunction with rising gasoline prices, which may have contributed to this development. We find that driving among those socio-demographic groups, who have better opportunities to reduce their driving, and driving for discretionary rather than commute purposes is being reduced over time. Sweden is ranked among the most gender-equal countries in the world; yet we find a substantial remaining gender gap in the share of adults driving a car on an average day, even when controlling for other socio-economic differences.
|
|
| 7. |
- Bastian, Anne
(författare)
-
Peak Car in Sweden?
- 2015
-
Licentiatavhandling (övrigt vetenskapligt/konstnärligt)abstract
- It has long been well-known that economic variables such as GDP and fuel price as well as socio-demographic characteristics and spatial distribution are key factors in explaining car use trends. However, due to the recently observed plateau of total car travel in many high income countries, it has been argued that other factors, such as changes in preferences, attitudes and life-styles, have become more important drivers of car use. This thesis shows that the two variables GDP per capita and fuel price explain most of the aggregate trends in car distances driven per adult in Sweden: as much as 80% over the years 2002 to 2012. The estimated elasticities are well in line with previous literature and can reasonably well reproduce the trend in car distances driven per adult back to 1980. We find, however, a substantial variation in elasticities between municipalities depending on public transport supply, population density, share of foreign-born inhabitants and the average income level. Swedish National Travel Survey data from 1978 to 2011 reveals that reductions in per adult driving mainly occurred among urban men. Urban men of all income groups reduced their driving for both commuting and non-commuting trips in conjunction with rising gasoline prices, which may have contributed to this development. We find that driving among those socio-demographic groups, who have better opportunities to reduce their driving, and driving for discretionary rather than commute purposes is being reduced over time. Sweden is ranked among the most gender-equal countries in the world; yet we find a substantial remaining gender gap in the share of adults driving a car on an average day, even when controlling for other socio-economic differences.
|
|
| 8. |
|
|
| 9. |
- Bastian, Anne, et al.
(författare)
-
The city as a driver of new mobility patterns, cycling and gender equality : Travel behaviour trends in Stockholm 1985–2015
- 2018
-
Ingår i: Travel Behaviour & Society. - : Elsevier Ltd. - 2214-367X .- 2214-3688. ; 13, s. 71-87
-
Tidskriftsartikel (refereegranskat)abstract
- This paper analyses changes in individual travel behaviour in Stockholm County over 30 years, using three large cross-sectional travel survey data sets. It shows that travel patterns have diverged over time between city, suburban and rural residents. The trends in travel behaviour that we find are consistent with changes in the labour market, ICT use, land-use and transport policy, gender equality, and population composition trends. The inner city has become increasingly attractive: the share of trips is to the inner city is increasing for all purposes, socio-economic groups, and residential locations. The reduction of car traffic in response to the introduction of the congestion charges in 2006 is more than compensated by an increase in bicycle and transit trips to the inner city. Travel times by car are increasing in the city, although the car traffic volumes have decreased. The travel behaviour gender gap has closed completely in the inner city, but not further out in the region or in the rest of the country. Understanding long term trends in travel behaviour in different population segments, and the context under which they occur, helps to understand how the conditions, opportunities and constraints for different population segments are changing, which is key for transport policy and land-use planning. Since the societal trends driving travel behaviour in Stockholm and Sweden are much the same in many cities and countries, the findings are of general relevance.
|
|
| 10. |
- Bastian, Anne, et al.
(författare)
-
The city as a driver of new mobility patterns, cycling and gender equality: Travel behaviour trends in Stockholm 1985-2015
-
Annan publikation (övrigt vetenskapligt/konstnärligt)abstract
- We analyse changes in individual travel behaviour in Stockholm County over 30 years, using three large cross-sectional travel survey data sets. We show how travel patterns evolve over time by gender, income and age-group, in different areas of the region (centre vs. periphery). We relate the observed trends in travel behaviour to societal trends (gender equality, ICT adoption, knowledge-based economy) and policy changes (congestion charges), and we compare them to trends in other European capital cities.
|
|
| 11. |
- Berglund, Henrik, 1973, et al.
(författare)
-
CBIs studie om innovationsledning
- 2011
-
Rapport (övrigt vetenskapligt/konstnärligt)abstract
- CBI har under andra halvåret 2010 och första halvåret 2011 genomfört en studie av innovationsledning hos 38 utvalda svenska företag inom tillverkning, IT och Telekom. Syftet var att undersöka hur företagen leder och organiserar innovation samt vilka utmaningar de står inför. Frågorna har besvarats av antingen VD eller en medlem i ledningsgruppen med insyn i företagets hantering av innovation.Resultatet visar att -de flesta företagen inte skiljer på radikal och inkrementell innovation-i många företag används ordet innovation för all produkt- och tjänsteutveckling-de flesta företag ser en ökning av innovationstakten inom sin respektive bransch-de flesta företag uttrycker att innovation är viktigt, samtidigt som få företag har innovationsfrågor bland sina tre största utmaningar-hälften av företagen använder någon form av rutin för att stärka sin förmåga att skapa nya produkter och tjänster, men endast ett fåtal använder flera olika rutiner-förstainnovationsföretagen (mindre, relativt nystartade företag) skiljer sig från de övriga i det att de är starkt innovationscentrerade-många företag välkomnar stöd från akademin, men endast ett fåtal önskar stöd att öka sin innovationsförmågaCBIs samtliga seniora forskare har genomfört intervjuerna.
|
|
| 12. |
- Bjerke, Maria, 1977, et al.
(författare)
-
Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years.
- 2016
-
Ingår i: Journal of Alzheimer's disease : JAD. - 1875-8908. ; 49:3, s. 733-741
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: Increased fatty acid-binding protein 3 (FABP-3) levels have been reported in neurodegenerative diseases, including Alzheimer's disease (AD). Cerebrospinal fluid (CSF) FABP-3 has therefore been proposed as a putative marker for dementia. Population-based studies examining whether CSF FABP-3 predicts later development of dementia are lacking. OBJECTIVE: The aim of this study was to examine CSF levels of FABP-3 in relation to later development of dementia in elderly women and in relation to Aβ42, T-tau, P-tau181, and CSF: serum albumin ratio. METHODS: 86 non-demented women aged 70-84 years who participated in the Prospective Population Study of Women in Gothenburg, Sweden took part in a lumbar puncture in 1992-93. CSF-FABP-3, Aβ42, T-tau, P-tau181, and the CSF: serum albumin ratio were measured at baseline. Participants were examined with a neuropsychiatric exam at baseline and at follow-up in 2000. Dementia was diagnosed in accordance with DSM-III-R criteria. RESULTS: Between 1992 and 2000, 8 women developed dementia (4 AD, 3 vascular dementia, 1 mixed vascular dementia and AD). Higher levels of CSF-FABP-3 at baseline were related to development of dementia (OR 1.36 CI [1.05-1.76] p=0.022) and the subtype AD (OR 1.38 CI [1.06-1.82), p=0.019) during follow-up. FABP-3 correlated with CSF T-tau (r=0.88, p< 0.001), P-tau181 (r=0.619, p< 0.001), and CSF:serum albumin ratio (r=0.233, p=0.031), but not with Aβ42 (r=-0.08, p=0.444)Conclusion: CSF FABP-3 may be an early marker for later development of dementia, probably related to neuronal degeneration, but independent of Aβ metabolism.
|
|
| 13. |
|
|
| 14. |
|
|
| 15. |
- Börjesson, Anne
(författare)
-
Digitala kompendier
- 2006
-
Konferensbidrag (övrigt vetenskapligt/konstnärligt)
|
|
| 16. |
|
|
| 17. |
- Börjesson, Anne
(författare)
-
La syntaxe de seul et seulement
- 2004
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- The overall aim of this study is to describe a number of different uses of the French "seul" and "seulement", and to account for the observed differences within a generative framework. After an introductory chapter, chapters two and three present a survey of earlier studies. The fourth chapter concerns an empirical study of authentic occurrences of "seul" and seulement", drawn from the press. The empirical study permits us to classify the occurrences into two sets of three groups on the basis of distributional, semantic and syntactic criteria. The fifth chapter shows that it is possible to account for the differences between these groups by a generative phrase structure model. In the first set of three groups, that of "seul", one of the groups includes the occurrences of "seul" that, by their ability to appear in attributive and predicative contexts, are characterized as descriptive adjectives. The next group of occurrences is supposed to correlate with the appearance of "seul" in a position between the article and the noun ("un/le seul N") within the functional layer of DP, specifically as an AP in Spec,NumP, a projection associated with grammatical number. The third group of occurrences differs from the two first, in so far as "seul" in this case is analysed as a quantifier, i.e. as the head of a QP situated immediately above DP. The second set of three groups encompass the occurrences of "seulement". These occurrences divide into groups mainly on the basis of their distribution. The occurrences of the first group are analysed as APs having access to the Spec position of DP/QP, AP and PP. The second group is interpreted in relation to the VP, either to the object or to the entire VP. In these cases, "seulement" is supposed to occur in a functional projection directly above VP. Finally, "seulement" may also appear within the CP layer. Its syntactical properties then closely resemble those of the conjunctions. The sixth chapter hints at the possibility that the different uses of "seul" and "seulement" may result from a grammaticalization process. The last chapter presents the conclusion of the study.
|
|
| 18. |
- Börjesson-Hanson, Anne, 1959
(författare)
-
Dementia and other mental disorders among 95-year olds
- 2008
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- The aims of this study were to estimate the prevalence of mental disorders and age related differences in the very elderly. In addition, five-year mortality after age 95 in relation to dementia and cognitive function in non-demented, was examined. A population sample of 338 95-year olds (response rate 65%) living in Gothenburg, Sweden, was compared with 85- (N=494) and 75-year olds (N=303) from the same birth cohort. All participants were examined by psychiatrists. The assessments included the Comprehensive Psychopathological Rating Scale, cognitive tests, the Mini Mental State Examination (MMSE), medical history, physical examination and a telephone interview with a key informant. Dementia, depression, anxiety and psychosis were classified according to DSM-III-R criteria, Alzheimer?s disease according to NINCDS-ADRDA criteria and vascular dementia (VaD) according to NINDS-AIREN criteria. Two-thirds (66%) of the 95-year olds fulfilled criteria for a mental disorder. Dementia was more common (52% vs. 30%; p<0.001) and more severe in 95-year olds than in 85-year olds. Among 95-year olds, dementia was more common in women than in men (56% vs. 37%; p=0.006). The proportion of VaD was lower among 95-year olds than among 85-year olds (30% vs. 40%; p<0.001). Almost one-third (29%) of the non-demented 95-year olds had a psychiatric disorder (depression 17%, anxiety disorders 9%, psychotic disorder 7%). Psychotic symptoms among non-demented 95-year olds were not associated with other psychiatric symptoms, sensory impairments or cognitive function. The prevalence of psychiatric disorders among non-demented was higher for 85- and 95-year olds than for 75-year olds. Five-year survival after age 95 was similar in men and women, but when controlling for dementia, male sex predicted mortality. Dementia was the leading predictor for death after age 95 and attributed to 40% of deaths. For each point increase in the MMSE score among the non-demented 95-year olds, mortality decreased by 13% (RR 0.87; p<0.0002). The high prevalence of psychiatric disorders emphasizes the importance of detecting and treating psychiatric problems among the oldest old, and also the need for further research on mental health in this age group. There is a concern that psychiatric symptoms among the very old are considered ?normal for age? and therefore neglected by the patients themselves, their relatives and health care professionals.
|
|
| 19. |
- Börjesson-Hanson, Anne, 1959, et al.
(författare)
-
Five-year mortality in relation to dementia and cognitive function in 95-year-olds.
- 2007
-
Ingår i: Neurology. - : Ovid Technologies (Wolters Kluwer Health). - 0028-3878 .- 1526-632X. ; 69:22, s. 2069-75
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: Dementia is a known predictor of mortality, but most studies include small numbers of participants above age 90. The influence of dementia or cognition on mortality in this age group is therefore uncertain. OBJECTIVE: To examine 5-year mortality in relation to dementia and cognitive performance at age 95. METHODS: A population sample of 338 individuals examined at age 95 was followed to age 100. Dementia was diagnosed according to DSM-III-R criteria. Cognitive function was measured using the Mini-Mental State Examination (MMSE). Information on severe physical disorders was obtained from the Swedish Hospital Discharge Register, and date of death from the Swedish Population Register. RESULTS: Five-year mortality was higher in 95-year-olds with dementia than in 95-year-olds without dementia (96% vs 73%; p < 0.0001), even when adjusting for severe physical disorders. A Cox regression analysis with calculation of population attributable risk (PAR), calculated from adjusted relative risks, showed that mortality was predicted by dementia (PAR 42%), cardiac disease (PAR 17%), cancer (PAR 6%), and male sex (PAR 7%), but not by stroke. Among the subjects without dementia, cognitive performance measured using the MMSE (n = 133 with complete tests; 81% of the subjects without dementia) predicted mortality. For each point increase in the MMSE, mortality decreased by 13%. CONCLUSIONS: In 95-year-olds, dementia, as well as cognitive performance in the subjects without dementia, influences mortality. When controlling for other severe medical conditions we found dementia to be the leading cause of deaths among the oldest old. The reason why dementia and cognitive function predict life expectancy requires further elucidation.
|
|
| 20. |
- Börjesson-Hanson, Anne, 1959, et al.
(författare)
-
One-Month Prevalence of Mental Disorders in a Population Sample of 95-Year Olds.
- 2011
-
Ingår i: The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. - 1545-7214. ; 19:3, s. 284-91
-
Tidskriftsartikel (refereegranskat)abstract
- OBJECTIVE:: To determine the 1-month prevalence of mental disorders among 95-year olds. DESIGN:: Cross-sectional population sample of 95-year olds. SETTING:: All 95-year olds born in the period 1901-1903 living in Gothenburg, Sweden, were invited. Elderly living in both community settings and nursing homes were included. PARTICIPANTS:: In total, 338 95-year olds (response rate: 65%) were examined (263 women, 75 men). MEASUREMENTS:: All participants were examined by psychiatrists using the Comprehensive Psychopathological Rating Scale and cognitive tests. Mental disorders were classified according to Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised criteria. RESULTS:: Two-third of all 95-year olds had a mental disorder. In the total sample of 95-year olds, the 1-month prevalence was 52% for dementia, 8% for depression, 4% for anxiety, and 3% for psychotic disorders. Almost one-third (29%) of the nondemented 95-year olds fulfilled criteria for a psychiatric disorder: 17% had depression, 9% anxiety, and 7% psychotic disorder. CONCLUSIONS:: The combined prevalence of mental disorders was high among 95-year olds, even after excluding dementia. These findings emphasize the importance of research, care, and detection of psychiatric problems in this age group.
|
|
| 21. |
|
|
| 22. |
- Börjesson, Maria, 1974-, et al.
(författare)
-
The economics of low emission zones
- 2021
-
Ingår i: Transportation Research Part A. - : Elsevier Ltd. - 0965-8564 .- 1879-2375. ; 153, s. 99-114
-
Tidskriftsartikel (refereegranskat)abstract
- This paper provides two microeconomic models that derive the social cost of a low emission zone (LEZ) for light vehicles. We apply the models to a proposed LEZ for light vehicles in Stockholm, which would prohibit diesel cars of Euro 5 or lower and gasoline cars of Euro 4 or lower in the inner city (25 km2) and conduct a cost-benefit analysis of the proposed LEZ. The first model is based on how an increase in user cost impacts traffic volumes in the inner city. This rather conventional user cost calculation of drivers’ loss requires however some strong assumptions. The second model shows that drivers’ losses can be calculated based on price changes observed on the used car market. Our empirical results indicate that the welfare loss resulting from the two models are of the same magnitude. The forecast benefits of the LEZ consist primarily of air quality improvements leading to health benefits. Even if our empirical results must be interpreted with caution, it seems clear that the costs considerably outweigh the benefits in this case study. © 2021 Elsevier Ltd
|
|
| 23. |
- Börjesson, Sofia, 1964, et al.
(författare)
-
Attention as a means to develop innovation capabilities
- 2020
-
Ingår i: International Journal of Business Innovation and Research. - 1751-0260 .- 1751-0252. ; 22:3, s. 342-358
-
Tidskriftsartikel (refereegranskat)abstract
- In this article, we explore how an innovation jam – an information technology (IT)-based tool to generate new ideas from employees in response to a call for ideas on a predefined theme – was used in two Swedish industrial firms, Volvo Cars and Volvo Group. Based on two qualitative retrospective case studies, we explore the notion of attention, and highlight the inherent ability of an innovation jam to promote attention. We discuss how attention can be used strategically to support the development of firm capabilities for innovation but point also to the risks involved. The paper contributes to emerging research on how firms develop the capabilities for innovation and highlights how attention can be used strategically.
|
|
| 24. |
- Craggs, L. J. L., et al.
(författare)
-
Clusterin/Apolipoprotein J immunoreactivity is associated with white matter damage in cerebral small vessel diseases
- 2016
-
Ingår i: Neuropathology and Applied Neurobiology. - : Wiley. - 0305-1846 .- 1365-2990. ; 42:2, s. 194-209
-
Tidskriftsartikel (refereegranskat)abstract
- AimBrain clusterin is known to be associated with the amyloid- deposits in Alzheimer's disease (AD). We assessed the distribution of clusterin immunoreactivity in cerebrovascular disorders, particularly focusing on white matter changes in small vessel diseases. MethodsPost-mortem brain tissues from the frontal or temporal lobes of a total of 70 subjects with various disorders including cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), cerebral amyloid angiopathy (CAA) and AD were examined using immunohistochemistry and immunofluorescence. We further used immunogold electron microscopy to study clusterin immunoreactivity in extracellular deposits in CADASIL. ResultsImmunostaining with clusterin antibodies revealed strong localization in arterioles and capillaries, besides cortical neurones. We found that clusterin immunostaining was significantly increased in the frontal white matter of CADASIL and pontine autosomal dominant microangiopathy and leukoencephalopathy subjects. In addition, clusterin immunostaining correlated with white matter pathology severity scores. Immunostaining in axons ranged from fine punctate deposits in single axons to larger confluent areas with numerous swollen axon bulbs, similar to that observed with known axon damage markers such as non-phosphorylated neurofilament H and the amyloid precursor protein. Immunofluorescence and immunogold electron microscopy experiments showed that whereas clusterin immunoreactivity was closely associated with vascular amyloid- in CAA, it was lacking within the granular osmiophilic material immunolabelled by NOTCH3 extracelluar domain aggregates found in CADASIL. ConclusionsOur results suggest a wider role for clusterin associated with white matter damage in addition to its ability to chaperone proteins for clearance via the perivascular drainage pathways in several disease states.
|
|
| 25. |
- Craggs, Lucinda, et al.
(författare)
-
Quantitative vascular pathology and phenotyping familial and sporadic cerebral small vessel diseases
- 2013
-
Ingår i: Brain Pathology. - : Wiley. - 1015-6305 .- 1750-3639. ; 23:5, s. 547-557
-
Tidskriftsartikel (refereegranskat)abstract
- We quantified vascular changes in the frontal lobe and basal ganglia of four inherited small vessel diseases (SVDs) including cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), pontine autosomal dominant microangiopathy and leukoencephalopathy (PADMAL), hereditary multi-infarct dementia of Swedish type (Swedish hMID), and hereditary endotheliopathy with retinopathy, nephropathy, and stroke (HERNS). Vascular pathology was most severe in CADASIL, and varied with marginally greater severity in the basal ganglia compared to the frontal lobe. The overall sclerotic index values in frontal lobe were in the order CADASIL≥HERNS>PADMAL>Swedish hMID>sporadic SVD, and in basal ganglia CADASIL>HERNS>Swedish hMID>PADMAL> sporadic SVD. The subcortical white matter was almost always more affected than any gray matter. We observed glucose transporter-1 (GLUT-1) protein immunoreactivities were most affected in the white matter indicating capillary degeneration whereas collagen IV (COL4) immunostaining was increased in PADMAL cases in all regions and tissue types. Overall, GLUT-1:COL4 ratios were higher in the basal ganglia indicating modifications in capillary density compared to the frontal lobe. Our study shows that the extent of microvascular degeneration varies in these genetic disorders exhibiting common end-stage pathologies but is the most aggressive in CADASIL.
|
|
| 26. |
- de Heus, R. A. A., et al.
(författare)
-
Blood Pressure Lowering With Nilvadipine in Patients With Mild-to-Moderate Alzheimer Disease Does Not Increase the Prevalence of Orthostatic Hypotension
- 2019
-
Ingår i: Journal of the American Heart Association. - : Ovid Technologies (Wolters Kluwer Health). - 2047-9980. ; 8:10
-
Tidskriftsartikel (refereegranskat)abstract
- Background-Hypertension is common among patients with Alzheimer disease. Because this group has been excluded from hypertension trials, evidence regarding safety of treatment is lacking. This secondary analysis of a randomized controlled trial assessed whether antihypertensive treatment increases the prevalence of orthostatic hypotension (OH) in patients with Alzheimer disease. Methods and Results-Four hundred seventy-seven patients with mild-to-moderate Alzheimer disease were randomized to the calcium-channel blocker nilvadipine 8 mg/day or placebo for 78 weeks. Presence of OH (blood pressure drop >= 20/>= 10 mm Hg after 1 minute of standing) and OH-related adverse events (dizziness, syncope, falls, and fractures) was determined at 7 follow-up visits. Mean age of the study population was 72.2 +/- 8.2 years and mean Mini-Mental State Examination score was 20.4 +/- 3.8. Baseline blood pressure was 137.8 +/- 14.0/77.0 +/- 8.6 mm Hg. Grade I hypertension was present in 53.4% (n=255). After 13 weeks, blood pressure had fallen by -7.8/-3.9 mm Hg for nilvadipine and by -0.4/-0.8 mm Hg for placebo (P<0.001). Across the 78-week intervention period, there was no difference between groups in the proportion of patients with OH at a study visit (odds ratio [95% CI] 1.1 [0.8-1.5], P 0.62), nor in the proportion of visits where a patient met criteria for OH, corrected for number of visits (7.7 +/- 13.8% versus 7.3 +/- 11.6%). OH-related adverse events were not more often reported in the intervention group compared with placebo. Results were similar for those with baseline hypertension. Conclusions-This study suggests that initiation of a low dose of antihypertensive treatment does not significantly increase the risk of OH in patients with mild-to-moderate Alzheimer disease.
|
|
| 27. |
- Dyer, A. H., et al.
(författare)
-
Cognitive Outcomes of Long-term Benzodiazepine and Related Drug (BDZR) Use in People Living With Mild to Moderate Alzheimer's Disease: Results From NILVAD
- 2020
-
Ingår i: Journal of the American Medical Directors Association. - : Elsevier BV. - 1525-8610. ; 21:2, s. 194-200
-
Tidskriftsartikel (refereegranskat)abstract
- Objective: Benzodiazepines and related drugs (BDZRs) have been associated with an increased risk of Alzheimer's disease (AD) in later life. Despite this, it remains unclear whether ongoing BDZR use may further accelerate cognitive decline in those diagnosed with mild to moderate AD. Design: This study was embedded within NILVAD, a randomized controlled trial of nilvadipine in mild to moderate AD. Cognition was measured at baseline and 18 months using the Alzheimer Disease Assessment Scale, Cognitive Subsection (ADAS-Cog). We assessed predictors of long-term BDZR use and analyzed the effect of ongoing BDZR use on ADAS-Cog scores at 18 months. Additionally, the impact of BDZR use on adverse events, incident delirium, and falls over 18-month follow-up was assessed adjusting for relevant covariates. Setting and Participants: 448 participants with mild to moderate AD recruited from 23 academic centers in 9 European countries. Results: Overall, 14% (62/448) were prescribed an ongoing BDZR for the study duration. Increasing total number of (non-BDZR) medications was associated with a greater likelihood of BDZR prescription (odds ratio 1.16, 95% confidence interval 1.05-1.29). At 18 months, BDZR use was not associated with greater cognitive decline on the ADAS-Cog controlling for baseline ADAS-Cog scores, age, gender, study arm, and other clinical covariates (beta = 1.62, -1.34 to 4.56). However, ongoing BDZR use was associated with a greater likelihood of adverse events [incidence rate ratio (IRR) 1.19, 1.05-1.34], incident delirium (IRR 2.31, 1.45-3.68), and falls (IRR 1.66, 1.02-2.65) over 18 months that persisted after robust adjustment for covariates. Conclusions and Implications: This study found no effect of ongoing BDZR use on ADAS-Cog scores in those with mild to moderate AD over 18 months. However, ongoing use of these medications was associated with an increased risk of adverse events, delirium, and falls. Thus, BDZR use should be avoided where possible and deprescribing interventions should be encouraged in older adults with AD. (C) 2019 AMDA - The Society for Post-Acute and Long-Term Care Medicine.
|
|
| 28. |
- Ehrnberger, Karin, 1977-, et al.
(författare)
-
The Androchair : Performing Gynaecology through the Practice of Gender Critical Design
- 2017
-
Ingår i: The Design Journal. - Abingdon : Routledge. - 1460-6925 .- 1756-3062. ; 20:2, s. 181-198
-
Tidskriftsartikel (refereegranskat)abstract
- This paper highlights the important role that design plays when it comes to women's overall experiences of ther gynaecological examination. It exemplifies how the examination can become renegotiable through the practice of a critical design. We will reflect this in the design of the contemporary gynaecological examination chair (GEC). We used women's experiences as a starting point for the design of an Androchair (a conceptual male equivalent of the GEC), in order to make the experiences critically visible. Inspired by the view of the gynaecological examination as a performance where the Androchair is represented as a prop and was placed on a stage as a discussion object during a public seminar. The Androchair allowed for both critical and multiple readings of the GEC and through that, the gynaecology examination at large. Moreover, it stimulated a discussion about alternative ideas towards achieving a more positive experience. © 2017 Informa UK Limited, trading as Taylor & Francis Group.
|
|
| 29. |
- Gislason, Thorsteinn, et al.
(författare)
-
Effect of diagnostic criteria on the prevalence of frontotemporal dementia in the elderly
- 2015
-
Ingår i: Alzheimer's & Dementia. - : Wiley. - 1552-5260 .- 1552-5279. ; 11:4, s. 425-433
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: Frontotemporal dementia (FTD) is believed to be rare in the elderly, and the influence of different criteria on the prevalence of FTD is unclear. METHODS: Population-based samples of 70- to 95-year-olds (n = 2462) in Gothenburg, Sweden, underwent neuropsychiatric examinations. Behavioral variant FTD (bvFTD) was diagnosed according to the International Behavioural Variant FTD Criteria Consortium (FTDC), the Frontotemporal Lobe Degeneration Consensus criteria, and the Lund-Manchester Research Criteria. A subset (n = 1074) underwent computerized tomography (CT) of the brain. RESULTS: The prevalence of bvFTD varied between 0.2% and 0.5% at age 70 to 79 years, between 2.5% and 3.6% at age 80 to 89 years, and between 1.7% and 2.2% at age 90 to 95 years. The agreement between different criteria was low to moderate (κ = 0.20-0.42). Among those with bvFTD according to FTDC, 93.3% had frontal and/or temporal lobar atrophy on CT, compared with 12.6% of those without bvFTD (P < .001). CONCLUSIONS: The prevalence of bvFTD was higher than expected in this population. To a large extent, different criteria captured different individuals.
|
|
| 30. |
- Hemdal, Bengt, et al.
(författare)
-
Can the average glandular dose in routine digital mammography screening be reduced? A pilot study using revised image quality criteria.
- 2005
-
Ingår i: Radiation protection dosimetry. - : Oxford University Press (OUP). - 0144-8420 .- 1742-3406. ; 114:1-3, s. 383-8
-
Tidskriftsartikel (refereegranskat)abstract
- There is a need for tools that in a simple way can be used for the evaluation of image quality related to clinical requirements in mammography. The aim of this work was to adjust the present European image quality criteria to be relevant also for digital mammography images, and to use as simple and as few criteria as possible. A pilot evaluation of the new set of criteria was made with mammograms of 28 women from a General Electric Senographe 2000D full-field digital mammography system. One breast was exposed using the standard automatic exposure mode, the other using about half of that absorbed dose. Three experienced radiologists evaluated the images using visual grading analysis technique. The results indicate that the new quality criteria can be used for the evaluation of image quality related to clinical requirements in digital mammography in a simple way. The results also suggest that absorbed doses for the mammography system used may be substantially reduced.
|
|
| 31. |
|
|
| 32. |
- Hemdal, Bengt, et al.
(författare)
-
Clinical evaluation of a new set of image quality criteria for mammography.
- 2005
-
Ingår i: Radiation protection dosimetry. - : Oxford University Press (OUP). - 0144-8420 .- 1742-3406. ; 114:1-3, s. 389-94
-
Tidskriftsartikel (refereegranskat)abstract
- The European Commission (EC) quality criteria for screen-film mammography are used as a tool to assess image quality. A new set of criteria was developed and initially tested in a previous study. In the present study, these criteria are further evaluated using screen-film mammograms that have been digitised, manipulated to simulate different image quality levels and reprinted on film. Expert radiologists have evaluated these manipulated images using both the original (EC) and the new criteria. A comparison of three different simulated dose levels reveals that the new criteria yield a larger separation of image criteria scores than the old ones. These results indicate that the new set of image quality criteria has a higher discriminative power than the old set and thus seems to be more suitable for evaluation of image quality in mammography.
|
|
| 33. |
- Höglund, Kina, 1976, et al.
(författare)
-
Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration
- 2017
-
Ingår i: Translational Psychiatry. - : Springer Science and Business Media LLC. - 2158-3188. ; 7
-
Tidskriftsartikel (refereegranskat)abstract
- Brain autopsy and biomarker studies indicate that the pathology of Alzheimer's disease (AD) is initiated at least 10-20 years before clinical symptoms. This provides a window of opportunity to initiate preventive treatment. However, this emphasizes the necessity for biomarkers that identify individuals at risk for developing AD later in life. In this cross-sectional study, originating from three epidemiologic studies in Sweden (n = 1428), the objective was to examine whether amyloid pathology, as determined by low cerebrospinal fluid (CSF) concentration of the 42 amino acid form of beta-amyloid (A beta 42), is associated with biomarker evidence of other pathological changes in cognitively healthy elderly. A total of 129 patients were included and CSF levels of A beta 42, total tau, tau phosphorylated at threonine 181 (p-tau), neurogranin, VILIP-1, VEGF, FABP3, A beta 40, neurofilament light, MBP, orexin A, BDNF and YKL-40 were measured. Among these healthy elderly, 35.6% (N=46) had CSF A beta 42 levels below 530 pg ml(-1). These individuals displayed significantly higher CSF concentrations of t-tau (P < 0.001), p-tau (181) (P < 0.001), neurogranin (P = 0.009) and FABP3 (P = 0.044) compared with amyloid-negative individuals. Our study indicates that there is a subpopulation among healthy older individuals who have amyloid pathology along with signs of ongoing neuronal and synaptic degeneration, as well as tangle pathology. Previous studies have demonstrated that increase in CSF tau and p-tau is a specific sign of AD progression that occurs downstream of the deposition of A beta. On the basis of this, our data suggest that these subjects are at risk for developing AD. We also confirm the association between APOE epsilon 4 and amyloid pathology in healthy older individuals.
|
|
| 34. |
- Isaksson, Mats, 1961, et al.
(författare)
-
Assessing 131I in thyroid by non-spectroscopic instruments - a European intercomparison exercise
- 2019
-
Ingår i: Radiation Measurements. - : Elsevier BV. - 1350-4487 .- 1879-0925. ; 128:September
-
Tidskriftsartikel (refereegranskat)abstract
- One of the issues of the Open Project for the European Radiation Research Area (OPERRA) was human thyroid monitoring in case of a large scale nuclear accident. This issue was covered in task 5.4 as project “CaThyMARA” (Child and Adult Thyroid Monitoring After Reactor Accident), which included several aspects of thyroid monitoring, e.g. screening of facilities able to perform thyroid monitoring in the European countries, dose estimation, modelling of detector response, and two intercomparison exercises. The intercomparison described in this paper focused on thyroid monitoring by non-spectrometric instruments, including gamma cameras and other instruments that were considered available for measurements made by members of the public. A total of 12 facilities from 7 European countries have participated and 43 various measuring devices have been evaluated. The main conclusion of this intercomparison is that the ability to make assessments of 131I activity in the thyroid to the exposed population after an accidental release must, on the average, be considered as good among the European laboratories taking part in this study. This intercomparison also gave the participants the possibility to calibrate the measuring devices for thyroid measurements of children where this procedure was not available before. A comprehensive report of the intercomparison is given.
|
|
| 35. |
- Jevric, Martyn, 1973, et al.
(författare)
-
Norbornadiene-Based Photoswitches with Exceptional Combination of Solar Spectrum Match and Long-Term Energy Storage
- 2018
-
Ingår i: Chemistry - A European Journal. - : Wiley. - 1521-3765 .- 0947-6539. ; 24:49, s. 12767-12772
-
Tidskriftsartikel (refereegranskat)abstract
- Norbornadiene-quadricyclane (NBD-QC) photoswitches are candidates for applications in solar thermal energy storage. Functionally, they rely on an intramolecular [2+2] cycloaddition reaction, which couples the S0 landscape on the NBD side to the S1 landscape on the QC side of the reaction and vice-versa. This commonly results in an unfavourable correlation between the first absorption maximum and the barrier for thermal back-conversion. This work demonstrates that this correlation can be counteracted by using steric repulsion to hamper the rotational motion of the side groups along the back-conversion path. It is shown that this modification reduces the correlation between the effective back-conversion barrier and the first absorption maximum and also increases the back-conversion entropy. The resulting molecules exhibit exceptionally long half-lives for their metastable forms without significantly affecting other properties, most notably solar spectrum match and storage density.
|
|
| 36. |
- Karlsson, Björn, 1981, et al.
(författare)
-
DSM-IV and DSM-5 Prevalence of Social Anxiety Disorder in a Population Sample of Older People
- 2016
-
Ingår i: The American journal of geriatric psychiatry. - : Elsevier BV. - 1064-7481 .- 1545-7214. ; 24:12, s. 1237-1245
-
Tidskriftsartikel (refereegranskat)abstract
- Objectives: To examine the prevalence of social anxiety disorders (SAD) with (DSM-IV) and without (DSM-5) the person's own assessment that the fear was unreasonable, in a population sample of older adults. Further, to determine whether clinical and sociodemographic correlates of SAD differ depending on the criteria applied. Design: Cross-sectional. Setting: General population in Gothenburg, Sweden. Participants: A random population-based sample of 75- and 85-year olds (N = 1200) without dementia. Measurements: Psychiatric research nurses carried out a semi-structured psychiatric examination including the Comprehensive Psychopathological Rating Scale. DSM-IV SAD was diagnosed with the Mini International Neuropsychiatric Interview. SAD was diagnosed according to DSM-IV and DSM-5 criteria. The 6-month duration criterion in DSM-5 was not applied because of lack of information. Other assessments included the Global Assessment of Functioning (GAF), the Brief Scale for Anxiety (BSA), and the Montgomery Asberg Depression Rating Scale (MADRS). Results: The 1-month prevalence of SAD was 2.5% (N = 30) when the unreasonable fear criterion was defined in accordance with DSM-IV and 5.1% (N = 61) when the DSM-5 criterion was applied. Clinical correlates (GAF, MADRS, and BSA) were worse in SAD cases identified by either procedure compared with all others, and ratings for those reporting unreasonable fear suggested greater (albeit nonsignificant) overall psychopathology. Conclusions: Shifting the judgment of how reasonable the fear was, from the individual to the clinician, doubled the prevalence of SAD. This indicates that the DSM-5 version might increase prevalence rates of SAD in the general population. Further studies strictly applying all DSM-5 criteria are needed in order to confirm these findings.
|
|
| 37. |
|
|
| 38. |
|
|
| 39. |
- Kern, Silke, et al.
(författare)
-
Does low-dose acetylsalicylic acid prevent cognitive decline in women with high cardiovascular risk? A 5-year follow-up of a non-demented population-based cohort of Swedish elderly women.
- 2012
-
Ingår i: BMJ Open. - : BMJ. - 2044-6055. ; 2:5
-
Tidskriftsartikel (refereegranskat)abstract
- Objective The aim of this study was to examine whether low-dose acetylsalicylic acid (ASA) influences the rate of cognitive change in elderly women. Design Prospective, population-based cohort study. Setting The city of Gothenburg, Sweden, including those living in private households as well as in residential care. Participants The sample was derived from the Prospective Population Study of Women and from the H70 Birth Cohort Study in Gothenburg, Sweden. Both samples were obtained from the Swedish Population Register, based on birth date, and included 789 (response rate 71%) women aged 70–92years. After the exclusion of individuals with dementia and users of warfarin, clopidogrel or heparin at baseline, 681 women were examined. Among all participants, 95.4% (N=601) had a high cardiovascular risk (CVD), defined as 10% or higher 10-year risk of any CVD event according to the Framingham heart study and 129 used low-dose ASA (75–160mg daily) at baseline. After 5years a follow-up was completed by 489 women. Primary outcome and secondary outcome measures Cognitive decline and dementia incidence in relation to the use of low-dose ASA and cardiovascular risk factors. Cognition was measured using the Mini Mental State Examination (MMSE), word fluency, naming ability and memory word tests. Dementia was diagnosed according to the DSM-III-R criterion. As secondary outcome incidence of stroke and peptic ulcer in relation to low-dose ASA use was studied. Results Women on regular low-dose ASA declined less on MMSE at follow-up than those not on ASA. This difference was even more pronounced in those who had ASA at both examinations (p=0.004 compared with never users; n=66 vs n=338). All other cognitive tests showed the same trends. There were no differences between the groups regarding short-term risk for dementia (N=41). Conclusion Low-dose ASA treatment may have a neuroprotective effect in elderly women at high cardiovascular risk.
|
|
| 40. |
|
|
| 41. |
- Kern, Silke, et al.
(författare)
-
Lower CSF interleukin-6 predicts future depression in a population-based sample of older women followed for 17 years
- 2013
-
Ingår i: Brain Behavior and Immunity. - : Elsevier BV. - 0889-1591. ; 32, s. 153-158
-
Tidskriftsartikel (refereegranskat)abstract
- Objective The literature regarding cerebrospinal fluid (CSF) cytokines in geriatric depression is sparse. The aim of this study was to examine associations between CSF interleukin-6 (IL-6) and related proinflammatory cytokines and current and future depression in a population-based sample of older women who were followed for 17 years. Methods 83 non-demented women aged 70–84 years who participated in the Prospective Population Study of Women in Gothenburg, Sweden took part in a lumbar puncture in 1992–3. CSF- IL-6, interleukin-1β (IL-1β), interleukin- 8 (IL-8) and tumor necrosis factor-α (TNF-α) were measured. Psychiatric symptoms were rated with the Comprehensive Psychopathological Rating Scale at baseline and at three subsequent face-to-face examinations. Depression (major or minor) was diagnosed in accordance with DSM-IV/DSM-IV research criteria. Results At baseline, women with ongoing depression had lower levels of IL-6 (p < 0.04), IL-8 (p < 0.05) and TNF-α (p < 0.05) compared with those without depression. In women without depression at baseline, lower CSF IL-6 levels predicted depression at one or more follow-up examination (p < 0.03). Results from the generalized linear mixed logistic model using all baseline and follow-up data on depression status and Mini Mental State Examination score showed a significant relationship between IL-6 and depression (p = 0.005 OR 0.370 CI [0.184–0.744]). Conclusion Lower levels of CSF IL-6 were associated with current depression and with future depression during a follow-up of almost two decades. Our findings suggest that lower levels of CSF IL-6 may be related to depression vulnerability in later life.
|
|
| 42. |
- Kern, Silke, et al.
(författare)
-
Prevalence of preclinical Alzheimer disease Comparison of current classification systems
- 2018
-
Ingår i: Neurology. - : Ovid Technologies (Wolters Kluwer Health). - 0028-3878 .- 1526-632X. ; 90:19
-
Tidskriftsartikel (refereegranskat)abstract
- Objective To determine the prevalence of preclinical Alzheimer disease (AD) according to current classification systems by examining CSF from a representative general population sample of 70-year-olds from Gothenburg, Sweden. The sample was derived from the population-based H70 Gothenburg Birth Cohort Studies in Gothenburg, Sweden. The participants (n = 322, age 70 years) underwent comprehensive neuropsychiatric, cognitive, and somatic examinations. CSF levels of beta-amyloid (A beta)(42), A beta(40), total tau, and phosphorylated tau were measured. Preclinical AD was classified according to criteria of the A/T/N system, Dubois 2016, National Institute on Aging-Alzheimer's Association (NIA-AA) criteria, and International Working Group-2 (IWG-2) criteria. Individuals with Clinical Dementia Rating score > 0 were excluded, leaving 259 cognitively unimpaired individuals. The prevalence of amyloid pathology was 22.8%, of total tau pathology was 33.2%, and of phosphorylated tau pathology was 6.9%. With the A/T/N system, the prevalence of A+/T-/N- was 13.1%, A+/T-/N+ was 7.3%, A+/T+/N+ was 2.3%, A-/T-/N+ was 18.9%, and A-/T+/N+ was 4.6%. When the Dubois criteria were applied, the prevalence of asymptomatic at risk for AD was 36.7% and of preclinical AD was 9.7%. With the NIA-AA criteria, the prevalence of stage 1 was 13.1% and stage 2 was 9.7%. With the IWG-2 criteria, the prevalence of asymptomatic at risk for AD was 9.7%. The APOE epsilon 4 allele was associated with several of the categories. Men more often had total tau pathology, A+/T-/N+, preclinical AD according to Dubois 2016, asymptomatic at risk for AD according to the IWG-2 criteria, and NIA-AA stage 2. The prevalence of pathologic AD markers was very common (46%) in a representative population sample of 70-year-olds. The clinical implications of these findings need to be scrutinized further in longitudinal studies.
|
|
| 43. |
|
|
| 44. |
- Klemedtson, Agnes, et al.
(författare)
-
‘I Think It’s Cool That You Can Go from Thinking That Exercising Is No Fun at All to Actually Kind of Loving It.’ : Experiences of Long-Term Regular Participation in Physical Activity in Adolescents Who Have or Have Had Obesity
- 2023
-
Ingår i: Physical Activity and Health. - London : Ubiquity Press. - 2515-2270. ; 7:1, s. 270-280
-
Tidskriftsartikel (refereegranskat)abstract
- Introduction: Childhood obesity is associated with cardiometabolic and psychosocial comorbidity, weight stigma, and premature adult mortality. Physical activity provides many health benefits for adolescents with obesity.Aim: The purpose of this study was to explore what experiences adolescents who have or have had obesity between 13–18 years of age have from long-term participation in regular physical activity in a lifestyle intervention.Method: Semi-structured interviews were performed with nine adolescents (five girls, four boys) ages 13–18 years who had been participating in physical activity in a regular way in this intervention. They had been participating for one to six years (average 2.8 years). Qualitative content analysis with an inductive approach was used to analyse the data.Result: The adolescent’s experiences of regular physical activity in this intervention was divided into three categories: 1) to experience the joy of movement; 2) to experience influence of the group; 3) to experience personal development. An inclusive and accepting group increased positive feelings of participation and they experienced that they achieved weight loss, improved self-esteem, and generally felt better when they started to be physically active.Conclusion: When adolescents who have or have had obesity are given the proper circumstances for physical activity, they experience it as fun and self-developing. It is important for adolescents to be allowed to be with friends with similar experiences and be among individuals they feel comfortable with and connected to. © 2023 The Author(s).
|
|
| 45. |
|
|
| 46. |
- Landen, Jaren W., et al.
(författare)
-
Ponezumab in mild-to-moderate Alzheimer's disease : Randomized phase II PET-PIB study
- 2017
-
Ingår i: Alzheimer's and Dementia: Translational Research and Clinical Interventions. - : Wiley. - 2352-8737. ; 3:3, s. 393-401
-
Tidskriftsartikel (refereegranskat)abstract
- Introduction The safety, pharmacokinetics, and effect on peripheral and central amyloid β (Aβ) of multiple doses of ponezumab, an anti-Aβ monoclonal antibody, were characterized in subjects with mild-to-moderate Alzheimer's disease treated for 1 year. Methods Subjects were aged ≥50 years with Mini–Mental State Examination scores 16 to 26. Cohort Q was randomized to ponezumab 10 mg/kg (n = 12) or placebo (n = 6) quarterly. Cohort M was randomized to a loading dose of ponezumab 10 mg/kg or placebo, followed by monthly ponezumab 7.5 mg/kg (n = 12) or placebo (n = 6), respectively. Results Ponezumab was generally well tolerated. Plasma concentrations increased dose dependently, but cerebrospinal fluid (CSF) penetration was low. Plasma Aβ increased dose dependently with ponezumab, but CSF biomarkers, brain amyloid burden, cognition, and function were not affected. Conclusions Both ponezumab dosing schedules were generally safe and well tolerated but did not alter CSF biomarkers, brain amyloid burden, or clinical outcomes.
|
|
| 47. |
- Larkin, Lesley, et al.
(författare)
-
Investigation of an international outbreak of multidrug-resistant monophasic Salmonella Typhimurium associated with chocolate products, EU/EEA and United Kingdom, February to April 2022
- 2022
-
Ingår i: Eurosurveillance. - : European Centre for Disease Prevention and Control. - 1025-496X .- 1560-7917. ; 27:15
-
Tidskriftsartikel (refereegranskat)abstract
- An extensive multi-country outbreak of multidrug-resistant monophasic Salmonella Typhimurium infection in 10 countries with 150 reported cases, predominantly affecting young children, has been linked to chocolate products produced by a large multinational company. Extensive withdrawals and recalls of multiple product lines have been undertaken. With Easter approaching, widespread product distribution and the vulnerability of the affected population, early and effective real-time sharing of microbiological and epidemiological information has been of critical importance in effectively managing this serious food-borne incident.
|
|
| 48. |
- Lawlor, B., et al.
(författare)
-
NILVAD protocol: A European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease
- 2014
-
Ingår i: BMJ Open. - : BMJ Publishing Group. - 2044-6055. ; 4:10
-
Tidskriftsartikel (refereegranskat)abstract
- Introduction: This study is a European multicentre, randomised, double-blind, placebo-controlled trial investigating the efficacy and safety of nilvadipine as a disease course modifying treatment for mild-to-moderate Alzheimer's disease (AD) in a phase III study that will run for a period of 82 weeks with a treatment period of 78 weeks. Methods and analysis: Adult patients, males and females over 50 years with mild-to-moderate AD as defined by the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's disease and Related Disorders Association (NINCDSADRDA) criteria, will be included in the study. It aims to recruit a total of 500 patients with AD; 250 in the nilvadipine group and 250 in the placebo group. Participants will be randomised to receive nilvadipine, an 8 mg overencapsulated, sustained release capsule, or a matching overencapsulated placebo (sugar pill) for a period of 78 weeks of treatment. The primary efficacy outcome measure in this study is the change in cognitive function as assessed by the Alzheimer's disease Assessment Scale (ADASCog 12) from baseline to the end of treatment duration (78 weeks). There are two key secondary outcome measures, the Clinical Dementia Rating Scale Sum of Boxes (CDRsb) and the Disability Assessment for Dementia (DAD). If a statistically significant effect is seen in the primary outcome, CDRsb will be considered to be a coprimary end point and only the DAD will contribute to the secondary outcome analysis. Ethics and dissemination: The study and all subsequent amendments have received ethical approval within each participating country according to national regulations. Each participant will provide written consent to participate in the study. All participants will remain anonymised throughout and the results of the study will be published in an international peerreviewed journal. Trial registration number EUDRACT Reference Number: 201200276427.
|
|
| 49. |
- Lawlor, B., et al.
(författare)
-
Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial
- 2018
-
Ingår i: Plos Medicine. - : Public Library of Science (PLoS). - 1549-1676. ; 15:9
-
Tidskriftsartikel (refereegranskat)abstract
- Background This study reports the findings of the first large-scale Phase III investigator-driven clinical trial to slow the rate of cognitive decline in Alzheimer disease with a dihydropyridine (DHP) calcium channel blocker, nilvadipine. Nilvadipine, licensed to treat hypertension, reduces amyloid production, increases regional cerebral blood flow, and has demonstrated antiinflammatory and anti-tau activity in preclinical studies, properties that could have diseasemodifying effects for Alzheimer disease. We aimed to determine if nilvadipine was effective in slowing cognitive decline in subjects with mild to moderate Alzheimer disease. NILVAD was an 18-month, randomised, placebo-controlled, double-blind trial that randomised participants between 15 May 2013 and 13 April 2015. The study was conducted at 23 academic centres in nine European countries. Of 577 participants screened, 511 were eligible and were randomised (258 to placebo, 253 to nilvadipine). Participants took a trial treatment capsule once a day after breakfast for 78 weeks. Participants were aged > 50 years, meeting National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's disease Criteria (NINCDS-ADRDA) for diagnosis of probable Alzheimer disease, with a Standardised Mini-Mental State Examination (SMMSE) score of >= 12 and < 27. Participants were randomly assigned to 8 mg sustained-release nilvadipine or matched placebo. The a priori defined primary outcome was progression on the Alzheimer's Disease Assessment Scale Cognitive Subscale-12 (ADAS-Cog 12) in the modified intention-to-treat (mITT) population (n = 498), with the Clinical Dementia Rating Scale sum of boxes (CDR-sb) as a gated co-primary outcome, eligible to be promoted to primary end point conditional on a significant effect on the ADAS-Cog 12. The analysis set had a mean age of 73 years and was 62% female. Baseline demographic and Alzheimer disease +/- specific characteristics were similar between treatment groups, with reported mean of 1.7 years since diagnosis and mean SMMSE of 20.4. The prespecified primary analyses failed to show any treatment benefit for nilvadipine on the co-primary outcome (p = 0.465). Decline from baseline in ADASCog 12 on placebo was 0.79 (95% CI, -0.07 +/- 1.64) at 13 weeks, 6.41 (5.33 +/- 7.49) at 52 weeks, and 9.63 (8.33 +/- 10.93) at 78 weeks and on nilvadipine was 0.88 (0.02 +/- 1.74) at 13 weeks, 5.75 (4.66 +/- 6.85) at 52 weeks, and 9.41 (8.09 +/- 10.73) at 78 weeks. Exploratory analyses of the planned secondary outcomes showed no substantial effects, including on the CDR-sb or the Disability Assessment for Dementia. Nilvadipine appeared to be safe and well tolerated. Mortality was similar between groups (3 on nilvadipine, 4 on placebo); higher counts of adverse events (AEs) on nilvadipine (1,129 versus 1,030), and serious adverse events (SAEs; 146 versus 101), were observed. There were 14 withdrawals because of AEs. Major limitations of this study were that subjects had established dementia and the likelihood that non-Alzheimer subjects were included because of the lack of biomarker confirmation of the presence of brain amyloid. The results do not suggest benefit of nilvadipine as a treatment in a population spanning mild to moderate Alzheimer disease.
|
|
| 50. |
- Lesén, Eva, 1982, et al.
(författare)
-
Psychotropic drug use in relation to mental disorders and institutionalization among 95-year-olds: a population-based study.
- 2011
-
Ingår i: International psychogeriatrics. - 1741-203X. ; 23:8, s. 1270-1277
-
Tidskriftsartikel (refereegranskat)abstract
- Background: The prevalence of psychotropic drug use is high among the elderly, but research on how psychotropic drugs are used among individuals aged 90 years and older is limited. An increased knowledge on this topic may contribute to improved prescribing patterns in this vulnerable population. The aim of this study was to assess the use of psychotropic drugs in relation to mental disorders and institutionalization among 95-year-olds and to identify use of potentially inappropriate psychotropic drugs. Methods: All 95-year-olds born in 1901–1903 living in nursing homes or community settings in Gothenburg, Sweden were invited to participate. The response rate was 65% and 338 95-year-olds were examined (263 women, 75 men). Psychotropic drug use in relation to mental disorders and institutionalization was assessed. Information on drug use was collected primarily from multi-dose drug dispensing lists. Participants were examined by trained psychiatrists using the Comprehensive Psychopathological Rating Scale and a battery of cognitive tests. Dementia, depression, anxiety and psychotic disorders were diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, third edition, revised (DSM-III-R). Results: Sixty percent of the 95-year-old participants used psychotropic drugs; hypnotics were most common (44%). Potentially inappropriate psychotropics were observed in one third (33%). Antidepressants were used by 7% of the participants without dementia who fulfilled criteria for a depressive disorder, while 56% used hypnotics and 30% used anxiolytics. Conclusions: The high prevalence of psychotropic drug use and the nonspecific nature of these treatments among 95-year-olds indicate a need for improvement in prescribing patterns.
|
|
